{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:18:20Z","timestamp":1783070300869,"version":"3.54.6"},"reference-count":35,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Neoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy (RC) is a standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), yet baseline tools to refine prognostic stratification remain limited. We aimed to develop and internally validate a clinicopathological nomogram integrating the neutrophil-to-lymphocyte ratio (NLR) to estimate event-free survival (EFS) in patients with MIBC treated with NAC. Methods: We retrospectively analyzed 210 patients with cT2\u2013T4aN0\u20131M0 MIBC treated with cisplatin-based NAC at two Spanish institutions between 2010 and 2021. Candidate predictors included demographic, clinicopathological, and routine laboratory variables. A multivariable Cox model with backward selection based on the Akaike information criterion (AIC) was used to derive the final model, and internal validation was performed using 1000 bootstrap resamples. Results: Sex, age, prior non\u2013muscle-invasive bladder cancer (NMIBC), and NLR were retained in the final nomogram. The model showed moderate discrimination, with a Harrell\u2019s c-index of 0.60 and an optimism-corrected c-index of 0.58. The nomogram stratified patients into low-, intermediate-, and high-risk groups, with median EFS not reached, 47.5 months, and 18.0 months, respectively. High-risk patients also showed lower pathological complete response (pCR) rates. Conclusions: This exploratory nomogram integrates an accessible systemic inflammatory marker with baseline clinical variables to identify patients with poorer outcomes despite NAC. External validation in contemporary cohorts is warranted before clinical implementation.<\/jats:p>","DOI":"10.3390\/cancers18132054","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:03:56Z","timestamp":1782349436000},"page":"2054","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7563-3812","authenticated-orcid":false,"given":"Mariona","family":"Figols","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Althaia Xarxa Assistencial Universit\u00e0ria de Manresa, C\/Dr. Joan Soler 1\u20133, 08243 Manresa, Spain"},{"name":"PhD Programme in Medicine and Biomedical Sciences, Doctoral School, University of Vic-Central University of Catalonia (UVic-UCC), C\/Dr. Junyent 1, 08500 Vic, Spain"},{"name":"Faculty of Medicine, University of Vic-Central University of Catalonia (UVicUCC), Can Baumann Ctra de Roda 70, 08500 Vic, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4236-0199","authenticated-orcid":false,"given":"Andrea","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Catalan Institute of Oncology, Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fernandez-Saor\u00edn","sequence":"additional","affiliation":[{"name":"CARE Program, Germans Trias i Pujol Research Institute (IGTP), Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"},{"name":"Badalona Applied Research Group in Oncology (B\u00b7ARGO), Catalan Institute of Oncology, Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Bautista","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Althaia Xarxa Assistencial Universit\u00e0ria de Manresa, C\/Dr. Joan Soler 1\u20133, 08243 Manresa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8856-5596","authenticated-orcid":false,"given":"Olatz","family":"Etxaniz","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Catalan Institute of Oncology, Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"},{"name":"CARE Program, Germans Trias i Pujol Research Institute (IGTP), Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"},{"name":"Badalona Applied Research Group in Oncology (B\u00b7ARGO), Catalan Institute of Oncology, Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Ruz","sequence":"additional","affiliation":[{"name":"Urology Department, Althaia Xarxa Assistencial Universit\u00e0ria de Manresa, C\/Dr. Joan Soler 1\u20133, 08243 Manresa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1639-8386","authenticated-orcid":false,"given":"Jose Luis","family":"Gago","sequence":"additional","affiliation":[{"name":"Urology Department, University Hospital Germans Trias i Pujol, Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"G\u00f3mez-D\u00edaz","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Althaia Xarxa Assistencial Universit\u00e0ria de Manresa, C\/Dr. Joan Soler 1\u20133, 08243 Manresa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Pardo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Catalan Institute of Oncology, Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"},{"name":"CARE Program, Germans Trias i Pujol Research Institute (IGTP), Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"},{"name":"Badalona Applied Research Group in Oncology (B\u00b7ARGO), Catalan Institute of Oncology, Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gal\u00ed","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Althaia Xarxa Assistencial Universit\u00e0ria de Manresa, C\/Dr. Joan Soler 1\u20133, 08243 Manresa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Bernal","sequence":"additional","affiliation":[{"name":"Urology Department, University Hospital Germans Trias i Pujol, Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Camps","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Catalan Institute of Oncology, Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Rifa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Althaia Xarxa Assistencial Universit\u00e0ria de Manresa, C\/Dr. Joan Soler 1\u20133, 08243 Manresa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Domenech","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Althaia Xarxa Assistencial Universit\u00e0ria de Manresa, C\/Dr. Joan Soler 1\u20133, 08243 Manresa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4352-1784","authenticated-orcid":false,"given":"Vicen\u00e7","family":"Ruiz de Porras","sequence":"additional","affiliation":[{"name":"GRET and Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1962-971X","authenticated-orcid":false,"given":"Anna","family":"Esteve","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Catalan Institute of Oncology, Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Font","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Catalan Institute of Oncology, Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"},{"name":"CARE Program, Germans Trias i Pujol Research Institute (IGTP), Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"},{"name":"Badalona Applied Research Group in Oncology (B\u00b7ARGO), Catalan Institute of Oncology, Cam\u00ed de les Escoles, s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/cncr.23848","article-title":"A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A retrospective experience","volume":"113","author":"Dash","year":"2008","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: A meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"(2005). Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol., 48, 202\u2013206.","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration, and Vale, C. (2003). Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet, 361, 1927\u20131934.","DOI":"10.1016\/S0140-6736(03)13580-5"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clgc.2020.02.014","article-title":"Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience","volume":"18","author":"Iyer","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2017.05.016","article-title":"Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis","volume":"72","author":"Bhindi","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/cncr.24052","article-title":"Mortality increases when radical cystectomy is delayed more than 12 weeks: Results from a Surveillance, Epidemiology, and End Results-Medicare analysis","volume":"115","author":"Gore","year":"2009","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"104236","DOI":"10.1016\/j.critrevonc.2023.104236","article-title":"Predictors of response to neoadjuvant therapy in urothelial cancer","volume":"194","author":"Tripathi","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.juro.2013.07.061","article-title":"Refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"191","author":"Culp","year":"2014","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102211","DOI":"10.1016\/j.clgc.2024.102211","article-title":"Markers in Identifying Pathological Complete Response Status in Muscle Invasive Bladder Cancer Patients Who Achieved Clinical Complete Response After Neoadjuvant Chemotherapy","volume":"22","author":"Piao","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101671","DOI":"10.1016\/j.adro.2024.101671","article-title":"A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy","volume":"10","author":"Harada","year":"2025","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1245\/s10434-024-16429-9","article-title":"Nomogram for the Pathological Complete Response After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients","volume":"32","author":"Shan","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clgc.2016.05.004","article-title":"Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer","volume":"15","author":"Buisan","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.eururo.2014.02.042","article-title":"Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy","volume":"66","author":"Viers","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chen, Z., Zhang, Y., and Chen, T. (2024). Prognostic value of neutrophil to lymphocyte ratio for patients with bladder cancer undergoing radical cystectomy: A systematic review and meta-analysis. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1463173"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102144","DOI":"10.1016\/j.clgc.2024.102144","article-title":"Prognostic Value of NLR, PLR, SII, and dNLR in Urothelial Bladder Cancer Following Radical Cystectomy","volume":"22","author":"Salari","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.urology.2016.06.007","article-title":"Development of a Preoperative Nomogram Incorporating Biomarkers of Systemic Inflammatory Response to Predict Nonorgan-confined Urothelial Carcinoma of the Bladder at Radical Cystectomy","volume":"95","author":"Lucca","year":"2016","journal-title":"Urology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00345-022-04147-4","article-title":"Nomogram based on baseline clinicopathological characteristics for predicting bladder cancer-specific survival to neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"40","author":"Font","year":"2022","journal-title":"World J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.clgc.2016.04.008","article-title":"The Clinical Use of the Neutrophil to Lymphocyte Ratio (NLR) in Urothelial Cancer: A Systematic Review","volume":"14","author":"Marchioni","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Suh, J., Jung, J.H., Jeong, C.W., Kwak, C., Kim, H.H., and Ku, J.H. (2019). Clinical Significance of Pre-treated Neutrophil-Lymphocyte Ratio in the Management of Urothelial Carcinoma: A Systemic Review and Meta-Analysis. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01365"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/BLC-170133","article-title":"The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study","volume":"4","author":"Kaiser","year":"2018","journal-title":"Bladder Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.euf.2020.07.002","article-title":"Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium","volume":"7","author":"Mir","year":"2021","journal-title":"Eur. Urol. Focus."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic Differences Between \u201cPrimary\u201d and \u201cSecondary\u201d Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e697","DOI":"10.1016\/j.clgc.2017.01.024","article-title":"Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer with Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy","volume":"15","author":"Buisan","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"639.e1","DOI":"10.1016\/j.urolonc.2020.01.010","article-title":"Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer","volume":"38","author":"Black","year":"2020","journal-title":"Urol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clgc.2019.11.007","article-title":"Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated with Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis","volume":"18","author":"Kimura","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1007\/s00345-021-03793-4","article-title":"Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer","volume":"39","author":"Black","year":"2021","journal-title":"World J. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clgc.2013.10.002","article-title":"Nonresponse to neoadjuvant chemotherapy for muscle-invasive urothelial cell carcinoma of the bladder","volume":"12","author":"Mossanen","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1245\/s10434-026-19090-6","article-title":"Prognostic Significance of Lymph Node Ratio for Overall Survival in Patients with Lymph Node-Positive Bladder Cancer Post-Radical Cystectomy and Chemotherapy: A Multicenter Cohort Analysis","volume":"33","author":"Wang","year":"2026","journal-title":"Ann. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Szeles, A., Kubik, A., Vancsa, S., Grunwald, V., Hadaschik, B., Acs, N., Hegyi, P., Nyirady, P., and Szarvas, T. (2025). Prognostic and predictive value of pre-treatment blood-based inflammatory biomarkers in patients with urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1554048"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"602.e1","DOI":"10.1016\/j.urolonc.2020.02.005","article-title":"The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients","volume":"38","author":"Ogihara","year":"2020","journal-title":"Urol. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2054\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:44:05Z","timestamp":1783068245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":35,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132054"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132054","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}